اخبار بازار

آخرین اخبار مالی و اقتصادی، تحولات بازار، گزارش‌ها و تحلیل‌های بازارهای مالی را در PipVero دنبال کنید.

منبع: Zacks Investment Research خبرگزاری
یک ماه پیش
سهام اهمیت متوسط
Macerich's Q2 FFO & Revenues Beat Estimates on Strong Portfolio NOI

Macerich's Q2 FFO & Revenues Beat Estimates on Strong Portfolio NOI

MAC's Q2 FFO and revenues top estimates as stronger portfolio NOI, occupancy gains and tenant demand fuel growth.

نمادهای مرتبط 1
MAC MAC
منبع: Zacks Investment Research
مشاهده منبع
0 0 0
ادامه مطلب
نظر
منبع: Zacks Investment Research خبرگزاری
یک ماه پیش
سهام اهمیت متوسط
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.

نمادهای مرتبط 1
HRMY HRMY
منبع: Zacks Investment Research
مشاهده منبع
Official Partner ITBFX Start Trading
0 0 0
ادامه مطلب
نظر
منبع: Seeking Alpha خبرگزاری
یک ماه پیش
سهام اهمیت متوسط
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated

Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated

Harmony Biosciences Holdings, Inc. has now elevated BP-205, its orexin-2 receptor agonist, to lead the pipeline. HRMY management has become even more specific about business development—exactly the kind of thing I thought was missing earlier. My updated valuation suggests most of the improvement is now reflected in the stock. I am, therefore, upgrading HRMY from Sell to Hold.

نمادهای مرتبط 1
HRMY HRMY
منبع: Seeking Alpha
مشاهده منبع
Official Partner ITBFX Start Trading
0 0 0
ادامه مطلب
نظر
منبع: Forbes خبرگزاری
یک ماه پیش
سهام اهمیت متوسط
SpaceX Shares Plunge 13% As Elon Musk's Fortune Sheds $80 Billion—Here's What Analysts Are Saying

SpaceX Shares Plunge 13% As Elon Musk's Fortune Sheds $80 Billion—Here's What Analysts Are Saying

Some brokerages appeared optimistic about SpaceX's quarterly earnings: JPMorgan analysts, who lifted their price target for shares to $240 from $225, wrote SpaceX is benefiting from “extreme vertical integration” while noting its “pace of change in AI is incredibly fast,” and that a step-up in AI infrastructure and higher monetization could push SpaceX's AI revenue to $100 billion in 2027. Wells Fargo analysts cut their price target for SpaceX shares to $215 from $230 amid broader caution about its AI spending, noting that SpaceX was “off to an ambitious start” and that revenue projections for 2027 and 2028 were higher than expected, but so were capital expenditure estimates.

نمادهای مرتبط 1
SPCX SPCX
منبع: Forbes
مشاهده منبع
0 0 0
ادامه مطلب
نظر
منبع: Schwab Network خبرگزاری
یک ماه پیش
سهام اهمیت متوسط
Why CFRA Holds a Sell Rating on SPCX

Why CFRA Holds a Sell Rating on SPCX

CFRA's Keith Snyder says "there was a lot to like" in SpaceX (SPCX) earnings, but he points to a red flag in the company's capex spending levels. He also likes the "firm" computing power contracts SpaceX holds but he wants to hear if the company can grow "on its own without renting out excess capacity.

نمادهای مرتبط 1
SPCX SPCX
منبع: Schwab Network
مشاهده منبع
0 0 0
ادامه مطلب
نظر
منبع: GlobeNewsWire خبرگزاری
یک ماه پیش
سهام اهمیت متوسط
BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026

SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session.

نمادهای مرتبط 1
BCDA BCDA
منبع: GlobeNewsWire
مشاهده منبع
0 0 0
ادامه مطلب
نظر